-
Ab175581-100μgLintuzumab (anti-CD33) is a humanized monoclonal antibody that targets CD33, a 67-kDa cell surface glycoprotein expressed on most myeloid leukemia cells.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
-
Ab175581-10mgLintuzumab (anti-CD33) is a humanized monoclonal antibody that targets CD33, a 67-kDa cell surface glycoprotein expressed on most myeloid leukemia cells.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
-
Ab175581-1mgLintuzumab (anti-CD33) is a humanized monoclonal antibody that targets CD33, a 67-kDa cell surface glycoprotein expressed on most myeloid leukemia cells.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
-
Ab175581-5mgLintuzumab (anti-CD33) is a humanized monoclonal antibody that targets CD33, a 67-kDa cell surface glycoprotein expressed on most myeloid leukemia cells.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
-
Ab175587-1mglulizumab pegol
-
Ab175587-5mglulizumab pegol
-
Ab175606-1mgmoxetumomab pasudotox
-
Ab175606-5mgmoxetumomab pasudotox
-
Ab170702-10mgPenpulimab (anti-PDCD1) is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
-
Ab170702-1mgPenpulimab (anti-PDCD1) is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
-
Ab170702-5mgPenpulimab (anti-PDCD1) is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
-
Ab169321-100μgRelatlimab (anti-LAG-3/CD223) is a human LAG-3 specific monoclonal antibody that binds to LAG-3 on T cells, restoring effector function of exhausted T cells. Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg